Publication:
Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.

Loading...
Thumbnail Image

Date

2020-10-29

Authors

Cismaru, Anca Liliana
Rudin, Deborah
Ibañez, Luisa
Liakoni, Evangelia
Bonadies, Nicolas
Kreutz, Reinhold
Carvajal, Alfonso
Lucena, Maria Isabel
Martin, Javier
Sancho Ponce, Esther

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (p

Description

MeSH Terms

Adult
Aged
Aged, 80 and over
Agranulocytosis
Biomarkers, Pharmacological
Case-Control Studies
Dipyrone
Europe
Female
Genetic Predisposition to Disease
Genome-Wide Association Study
Germany
Humans
Male
Middle Aged
Neutropenia
Retrospective Studies
Switzerland

DeCS Terms

CIE Terms

Keywords

dipyrone, drug-induced agranulocytosis, genome-wide association study, metamizole, pharmacogenetics

Citation